Cipher Pharma Revenue, Profits - CPHR Quarterly Income Statement

Add to My Stocks
$2.99 $0 (0%) CPHR stock closing price Dec 08, 2016 (Closing)

CPHR stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Cipher Pharma stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from 11.7M to 9.27M and how operating and non operating activities have impacted the CPHR stock. One also needs to look at Cipher Pharma assets, operating expenses and Cipher Pharma free cash flow. The Cipher Pharma profit and loss statement shows revenue of $9.27M for 2016 Q3. Revenue has decreased by -20.77% QoQ for CPHR stock.

View and download details of revenue and profits for Cipher Pharma for latest & last 40 quarters.
show more
Fiscal year is Jan - Dec2016 Q32016 Q22016 Q12015 Q4
Cipher Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)-1.06M--
Cipher Pharma Gross Profit
Research & Development Expense----
Selling General & Admin Expense10.36M8.43M7.5M8.29M
Income Before Depreciation Depletion Amortization-1.98M1.87M--
Depreciation Depletion Amortization18.74M1.61M1.47M2.94M
Non Operating Income1.12M-0.03M-0.04M1.15M
Interest Expense1.85M3.14M1.33M1.32M
Cipher Pharma Pretax Income
Provision for Income Taxes----5.02M
Investment Gains Losses----
Other Income----
Income Before Extraordinaries & Disc Operations-21.79M-3.4M-2.69M2.04M
Extraordinary Items & Discontinued Operations----
Cipher Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS27.5M26.15M26.09M25.94M
Average Shares used to compute Basic EPS26.8M26.15M26.09M25.94M
Income Before Nonrecurring Items-2.19M-1.6M-2.69M1.91M
Income from Nonrecurring Items-19.6M-1.8M--
Cipher Pharma Earnings Per Share Basic Net
Cipher Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.08-0.06-0.100.07
Preferred Dividends Acc Pd----
Dividends Common----
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.

Click here to view our Taro Pharma financial analysis

Before investing one should read a report on Cipher Pharma stock analysis. It helps to look at the following income statement items:

  • Topline: A growing topline, as seen from the Cipher Pharma revenue chart, as isn't the case with Cipher Pharma indicates a sagging business. One needs to compare the QoQ topline or sales growth of CPHR stock with its peers like KMPH stock and ELTP stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-21.79M for CPHR stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the CPHR income statement, one can check the Cipher Pharma historical stock prices to check how the price has moved with time.

Cipher Pharma Income Statement - Key Financial Ratios